Developing the science base for reducing tobacco harm

Nicotine and Tobacco Research

Volumn 9, Issue SUPPL. 4, 2007, Pages 537-553

  Hatsukami, Dorothy ^a   Joseph, Anne ^a   LeSage, Mark ^a   Jensen, Joni ^a   Murphy, Sharon ^a   Pentel, Paul ^a   Kotlyar, Michael ^a   Borgida, Eugene ^a   Le, Chap ^a   Hecht, Stephen ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; AMFEBUTAMONE; BIOLOGICAL MARKER; CARBON MONOXIDE; COTININE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; GLUCURONIDE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NITROSAMINE; NORTRIPTYLINE; TOBACCO SMOKE;

BEHAVIORAL RESEARCH; DEVICE; DRUG DOSE INCREASE; DRUG MEGADOSE; GENETIC POLYMORPHISM; GENOTYPE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH HAZARD; HUMAN; MENTAL DISEASE; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK REDUCTION; SAFETY; SELF MEDICATION; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TOXICITY TESTING; TRANSDERMAL PATCH;

HUMANS; MODELS, THEORETICAL; RISK REDUCTION BEHAVIOR; SMOKING; SMOKING CESSATION; TOBACCO;

EID: 37049021779     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1080/14622200701679040     Document Type: Review

References (110)

1. Baker, T. B., Hatsukami, D. K., Lerman, C., O'Malley, S. S., Shields, A. E. and Fiore, M. C. (2003) Transdisciplinary science applied to the evaluation of treatments for tobacco use. Nicotine & Tobacco Research, 5, pp. S89-S99.
2. Benhamou, E., Benhamou, S., Auquier, A. and Flamant, R. (1989) Changes in patterns of cigarette smoking and lung cancer risk: Results of a case-control study. British Journal of Cancer, 60:4, pp. 601-604.
3. Benowitz, N. and Henningfield, J. E. (1994) Establishing a nicotine threshold for addiction. The New England Journal of Medicine, 331, pp. 123-125.
4. Benowitz, N. and Jacob, P. 3rd. (1993) Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clinical Pharmacology and Therapeutics, 53:3, pp. 316-323.
5. Benowitz, N. and Jacob, P. 3rd. (2000) Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clinical Pharmacology and Therapeutics, 67:6, pp. 653-659.
6. Benowitz, N., Perez-Stable, E. J., Fong, I., Modin, G., Herrera, B. and Jacob, P. 3rd. (1999) Ethnic differences in N-glucuronidation of nicotine and cotinine. The Journal of Pharmacology and Experimental Therapeutics, 291:3, pp. 1196-1203.
7. Benowitz, N., Zevin, S. and Jacob, P. III. (1998) Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. The Journal of Pharmacology and Experimental Therapeutics, 287:3, pp. 958-962.
8. Bernert, J. T., Jain, R. B., Pirkle, J. L., Wang, L., Miller, B. B. and Sampson, E. J. (2005) Urinary tobacco-specific nitrosamines and 4-aminobiphenyl hemoglobin adducts measured in smokers of either regular or light cigarettes. Nicotine & Tobacco Research, 7:5, pp. 729-738.
9. Bjartveit, K. and Tverdal, A. (2005) Health consequences of smoking 1-4 cigarettes per day. Tobacco Control, 14:5, pp. 315-320.
10. Boffetta, P., Aagnes, B., Weiderpass, E. and Andersen, A. (2005) Smokeless tobacco use and risk of cancer of the pancreas and other organs. International Journal of Cancer, 114:6, pp. 992-995.
11. Bolliger, C. T., Zellweger, J. P., Danielsson, T., van Biljon, X., Robidou, A., Westin, A., Perruchoud, A. P. and Sawe, U. (2002) Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine & Tobacco Research, 4:4, pp. 433-439.
12. Bowman, D. L., Smith, C. J., Bombick, B. R., Avalos, J. T., Davis, R. A., Morgan, W. T. and Doolittle, D. J. (2002) Relationship between FTC 'tar' and urine mutagenicity in smokers of tobacco-burning or Eclipse cigarettes. Mutation Research, 521:1, pp. 137-149.
13. Breland, A. B., Acosta, M. C. and Eissenberg, T. (2003) Tobacco specific nitrosamines and potential reduced exposure products for smokers: A preliminary evaluation of Advance. Tobacco Control, 12:3, pp. 317-321.
14. Breland, A. B., Buchhalter, A. R., Evans, S. E. and Eissenberg (2002) Evaluating acute effects of potential reduced-exposure products for smokers: Clinical laboratory methodology. Nicotine & Tobacco Research, 4, pp. S131-S140.
15. Breland, A. B., Kleykamp, B. A. and Eissenberg, T. (2006) Clinical laboratory evaluation of potential reduced exposure products for smokers. Nicotine & Tobacco Research, 8:6, pp. 727-738.
16. Buchhalter, A. R. and Eissenberg, T. (2000) Preliminary evaluation of a novel smoking system: Effects on subjective and physiological measures and on smoking behavior. Nicotine & Tobacco Research, 2:1, pp. 39-43.
17. Buchhalter, A. R., Schrinel, L. and Eissenberg, T. (2001) Withdrawal-suppressing effects of a novel smoking system: Comparison with own brand, not own brand, and de-nicotinized cigarettes. Nicotine & Tobacco Research, 3:2, pp. 111-118.
18. Burns, D. (1997) Estimating the benefits of a risk reduction strategy
19. Burns, D. (2003) Epidemiology of smoking-induced cardiovascular disease. Progress in Cardiovascular Disease, 46:1, pp. 11-29.
20. Carmella, S. G., Ka, A. Le, Upadhyaya, P. and Hecht, S. S. (2002) Analysis of N- and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Chemical Research in Toxicology, 15:4, pp. 545-550.
21. Carpenter, M. J., Hughes, J. R., Solomon, L. J. and Callas, P. W. (2004) Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. Journal of Consulting and Clinical Psychology, 72:3, pp. 371-381.
22. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. pp. 1121-1124.
23. Chen, L., Wang, M., Villalta, P. W., Luo, X., Feuer, R., Jensen, J., Hatsukami, D. K. and Hecht, S. S. (2007) Quantitation of an acetaldehyde adduct in human leukocyte DNA and the effect of smoking cessation. Chemical Research in Toxicology, 20:1, pp. 108-113.
24. Doll, R. and Peto, R. (1978) Cigarette smoking and bronchial carcinoma: Dose and time relationships among regular smokers and lifelong non-smokers. Journal of Epidemiology and Community Health, 32:4, pp. 303-313.
25. Doll, R., Peto, R., Boreham, J. and Sutherland, I. (2004) Mortality in relation to smoking: 50 years' observations on male British doctors. British Medical Journal, 328:7455, pp. 1519-1528.
26. Eliasson, B., Hjalmarson, A., Kruse, E., Landfeldt, B. and Westin, A. (2001) Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine & Tobacco Research, 3:3, pp. 249-255.
27. Etter, J., Paernegger, T. and Ronchi, A. (1997) Distributions of smokers by stage: International comparison and association with smoking prevalence. Preventive Medicine, 26, pp. 580-585.
28. Fagerström, K. O., Hughes, J. R. and Callas, P. W. (2002) Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. Nicotine & Tobacco Research, 4, pp. S141-S145.
29. Fagerström, K. O., Hughes, J. R., Rasmussen, T. and Callas, P. W. (2000) Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tobacco Control, 9:3, pp. 327-333.
30. Flanders, W. D., Lally, C. A., Zhu, B. P., Henley, S. J. and Thun, M. J. (2003) Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: Results from Cancer Prevention Study II. Cancer Research, 63:19, pp. 6556-6562.
31. Foulds, J., Ramstrom, L., Burke, M. and Fagerström, K. (2003) Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tobacco Control, 12:4, pp. 349-359.
32. Frampton, M. W., Hyde, R. W. and Torres, A. (2000) Lung injury and inflammation in smokers: Effects of switching to a "new" cigarette
33. Furberg, H., Bulik, C. M., Lerman, C., Lichtenstein, P., Pedersen, N. L. and Sullivan, P. F. (2005) Is Swedish snus associated with smoking initiation or smoking cessation?. Tobacco Control, 14:6, pp. 422-424.
34. Godtfredsen, N. S., Holst, C., Prescott, E., Vestbo, J. and Osler, M. (2002) Smoking reduction, smoking cessation, and mortality: A 16-year follow-up of 19,732 men and women from the Copenhagen Centre for Prospective Population Studies. American Journal of Epidemiology, 156:11, pp. 994-1001.
35. Godtfredsen, N. S., Osler, M., Vestbo, J., Andersen, I. and Prescott, E. (2003) Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: A pooled cohort study. Journal of Epidemiology and Community Health, 57:6, pp. 412-416.
36. Godtfredsen, N. S., Prescott, E. and Osler, M. (2005) Effect of smoking reduction on lung cancer risk. The Journal of the American Medical Association, 294:12, pp. 1505-1510.
37. Godtfredsen, N. S., Vestbo, J., Osler, M. and Prescott, E. (2002) Risk of hospital admission for COPD following smoking cessation and reduction: A Danish population study. Thorax, 57:11, pp. 967-972.
38. Gray, N., Henningfield, J. E., Benowitz, N. L., Connolly, G. N., Dresler, C., Fagerström, K., Jarvis, M. J. and Boyle, P. (2005) Toward a comprehensive long term nicotine policy. Tobacco Control, 14:3, pp. 161-165.
39. Harris, J. E., Thun, M. J., Mondul, A. M. and Calle, E. E. (2004) Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982-8. British Medical Journal, 328:7431, p. 72.
40. Hatsukami, D., Benowitz, N. L., Rennard, S. I., Oncken, C. and Hecht, S. S. (2006) Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine & Tobacco Research, 8:4, pp. 599-622.
41. Hatsukami, D., Ebbert, J. O., Anderson, A., Lin, H., Le, C. and Hecht, S. S. (2007) Smokeless tobacco brand switching: A means to reduce toxicant exposure?. Drug and Alcohol Dependence, 87:2, pp. 217-224.
42. Hatsukami, D., Giovino, G. A., Eissenberg, T., Clark, P. I., Lawrence, D. and Leischow, S. (2005) Methods to assess potential reduced exposure products. Nicotine & Tobacco Research, 7:6, pp. 827-844.
43. Hatsukami, D., Kotlyar, M., Allen, S., Jensen, J., Li, S., Le, C. and Murphy, S. (2005) Effects of cigarette reduction on cardiovascular risk factors and subjective measures. Chest, 128:4, pp. 2528-2537.
44. Hatsukami, D., Le, C. T., Zhang, Y., Joseph, A. M., Mooney, M. E., Carmella, S. G. and Hecht, S. S. (2006) Toxicant exposure in cigarette reducers versus light smokers. Cancer Epidemiology, Biomarkers, and Prevention, 15:12, pp. 2355-2358.
45. Hatsukami, D., Lemmonds, C., Zhang, Y., Murphy, S. E., Le, C., Carmella, S. G. and Hecht, S. S. (2004) Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. Journal of the National Cancer Institute, 96:11, pp. 844-852.
46. Hatsukami, D., Mooney, M., Murphy, S., LeSage, M., Babb, D. and Hecht, S. (2007) Effects of high dose transdermal nicotine replacement in cigarette smokers. Pharmacology, Biochemistry, and Behavior, 86:1, pp. 132-139.
47. Haustein, K. O., Krause, J., Haustein, H., Rasmussen, T. and Cort, N. (2004) Changes in hemorheological and biochemical parameters following short-term and long-term smoking cessation induced by nicotine replacement therapy (NRT). International Journal of Clinical Pharmacology and Therapeutics, 42:2, pp. 83-92.
48. Hecht, S. S. (2002) Human urinary carcinogen metabolites: Biomarkers for investigating tobacco and cancer. Carcinogenesis, 23:6, pp. 907-922.
49. Hecht, S. S., Carmella, S. G., Le, K. A., Murphy, S. E., Li, Y. S., Le, C., Jensen, J. and Hatsukami, D. K. (2004) Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine. Cancer Epidemiology, Biomarkers, and Prevention, 13:5, pp. 834-842.
50. Hecht, S. S., Carmella, S. G., Yoder, A., Chen, M., Li, Z. Z., Le, C., Dayton, R., Jensen, J. and Hatsukami, D. K. (2006) Comparison of polymorphisms in genes involved in polycyclic aromatic hydrocarbon metabolism with urinary phenanthrene metabolite ratios in smokers. Cancer Epidemiology, Biomarkers, and Prevention, 15:10, pp. 1805-1811.
51. Hecht, S. S., Chen, M., Yagi, H., Jerina, D. M. and Carmella, S. G. (2003) r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene in human urine: A potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiology, Biomarkers, and Prevention, 12:12, pp. 1501-1508.
52. Hecht, S. S., Murphy, S. E., Carmella, S. G., Li, S., Jensen, J., Le, C., Joseph, A. M. and Hatsukami, D. K. (2005) Similar uptake of lung carcinogens by smokers of regular, light, and ultralight cigarettes. Cancer Epidemiology, Biomarkers, and Prevention, 14:3, pp. 693-698.
53. Henley, S. J., Connell, C. J., Richter, P., Husten, C., Pechacek, T., Calle, E. E. and Thun, M. J. (2007) Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tobacco Control, 16:1, pp. 22-28.
54. Henningfield, J. (1995) Introduction to tobacco harm reduction as a complementary strategy to smoking cessation. Tobacco Control, 4, pp. S25-S28.
55. Hughes, J. R. (1995) Applying harm reduction to smoking. Tobacco Control, 4, pp. 533-538.
56. Hughes, J. R. and Carpenter, M. J. (2005) The feasibility of smoking reduction: An update. Addiction, 100:8, pp. 1074-1089.
57. Hughes, J. R. and Carpenter, M. J. (2006) Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine & Tobacco Research, 8:6, pp. 739-749.
58. Hughes, J. R., Hecht, S. S., Carmella, S. G., Murphy, S. E. and Callas, P. (2004) Smoking behaviour and toxin exposure during six weeks use of a potential reduced exposure product: Omni. Tobacco Control, 13:2, pp. 175-179.
59. Hughes, J. R., Keely, J. P. and Callas, P. W. (2005) Ever users versus never users of a "less risky" cigarette. Psychology of Addictive Behaviors, 19:4, pp. 439-442.
60. Hukkanen, J., Jacob, P. 3rd. and Benowitz, N. L. (2005) Metabolism and disposition kinetics of nicotine. Pharmacological Reviews, 57:1, pp. 79-115.
61. Hund, L. M., Farrelly, M. C., Allen, J. A., Chou, R. H., Claire, W. St., Vallone, D. M. and Healton, C. G. (2006) Findings and implications from a national study on potential reduced exposure products (PREPs). Nicotine & Tobacco Research, 8:6, pp. 791-797.
62. Jacob, P. 3rd., Wilson, M. and Benowitz, N. L. (2007) Determination of phenolic metabolites of polycyclic aromatic hydrocarbons in human urine as their pentafluorobenzyl ether derivatives using liquid chromatography-tandem mass spectrometry. Analytical Chemistry, 79:2, pp. 587-598.
63. Jimenez-Ruiz, C., Kunze, M. and Fagerström, K. (1998) Nicotine replacement: A new approach to reducing tobacco-related harm. European Respiratory Journal, 11:2, pp. 263-264.
64. Joseph, A. M., Bliss, R. L., Zhao, F. and Lando, H. (2005) Predictors of smoking reduction without formal intervention. Nicotine & Tobacco Research, 7:2, pp. 277-282.
65. Joseph, A. M., Hecht, S. S., Murphy, S. E., Lando, H., Carmella, S. G., Han, S., Gross, M., Bliss, R., Le, C. T. and Hatsukami, D. K. Smoking reduction fails to improve clinical and biological biomarkers of cardiac disease: A randomized controlled trial. Nicotine & Tobacco Research
66. Joseph, A. M., Hennrikus, D., Thoele, M. J., Krueger, R. and Hatsukami, D. (2004) Community tobacco control leaders' perceptions of harm reduction. Tobacco Control, 13:2, pp. 108-113.
67. Kawachi, I., Colditz, G. A., Stampfer, M. J., Willett, W. C., Manson, J. E., Rosner, B., Speizer, F. E. and Hennekens, C. H. (1994) Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Archives of Internal Medicine, 154:2, pp. 169-175.
68. Lemmonds, C. A., Mooney, M., Reich, B. and Hatsukami, D. (2004) Characteristics of cigarette smokers seeking treatment for cessation versus reduction. Addictive Behaviors, 29:2, pp. 357-364.
69. LeSage, M. G., Burroughs, D. and Pentel, P. R. (2006) Compensatory nicotine self-administration during reduced access to nicotine: An animal model of nicotine exposure reduction
70. LeSage, M. G., Keyler, D. E., Collins, G. and Pentel, P. R. (2003) Effects of continuous nicotine infusion on nicotine self-administration in rats: Relationship between continuously infused and self-administered nicotine doses and serum concentrations. Psychopharmacology, 170:3, pp. 278-286.
71. LeSage, M. G., Keyler, D. E., Shoeman, D., Raphael, D., Collins, G. and Pentel, P. R. (2002) Continuous nicotine infusion reduces nicotine self-administration in rats with 23-h/day access to nicotine. Pharmacology, Biochemistry, and Behavior, 72:1, pp. 279-289.
72. Levy, D. T., Mumford, E. A., Cummings, K. M., Gilpin, E. A., Giovino, G., Hyland, A., Sweanor, D. and Warner, K. E. (2004) The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: Estimates of a panel of experts. Cancer Epidemiology, Biomarkers, and Prevention, 13:12, pp. 2035-2042.
73. Lewin, F., Norell, S., Johansson, H., Gustavsson, P. and Wennerberg, J. (1998) Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck. Cancer, 82, pp. 1367-1374.
74. Lubin, J. H. (1984) Modifying risk of developing lung cancer by changing habits of cigarette smoking. British Medical Journal, 289:6449, p. 921.
75. MacCoun, R. J. (1998) Toward a psychology of harm reduction. American Psychologist, 53:11, pp. 1199-1208.
76. Malaiyandi, V., Sellers, E. M. and Tyndale, R. F. (2005) Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clinical Pharmacology and Therapeutics, 77:3, pp. 145-158.
77. Martin, E. G., Warner, K. E. and Lantz, P. M. (2004) Tobacco harm reduction: What do the experts think?. Tobacco Control, 13:2, pp. 123-128.
78. Mendoza-Baumgart, M. I., Hecht, S. S., Zhang, Y., Murphy, S. E., Le, C., Jensen, J. and Hatsukami, D. K. Pilot study on lower nitrosamine smokeless tobacco products compared to medicinal nicotine. Nicotine & Tobacco Research
79. Menotti, A., Blackburn, H., Kromhout, D., Nissinen, A., Adachi, H. and Lanti, M. (2001) Cardiovascular risk factors as determinants of 25-year all-cause mortality in the seven countries study. European Journal of Epidemiology, 17, pp. 337-346.
80. National Cancer Institute (2001) Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine, U.S. Department of Health and Human Services, National Institutes of Health, Author, Bethesda, MD
81. Norberg, M., Stenlund, H., Lindahl, B., Boman, K. and Weinehall, L. (2006) Contribution of Swedish moist snuff to the metabolic syndrome: A wolf in sheep's clothing?. Scandinavian Journal of Public Health, 34, pp. 576-583.
82. Phillips, J. M., Siegel, S. J., Shields, A. E., Patterson, F., Gould, T. J., Strasser, A. A., Ray, R., Pinto, A., Audrain-McGovern, J., Rukstalis, M., Perkins, K. A., Blendy, J. A. and Lerman, C. (2007) Translating basic science to improve pharmacotherapy for nicotine dependence. Nicotine & Tobacco Research
83. Ramstrom, L. M. and Foulds, J. (2006) Role of snus in initiation and cessation of tobacco smoking in Sweden. Tobacco Control, 15:3, pp. 210-214.
84. Rennard, S. I., Umino, T., Millatmal, T., Daughton, D. M., Manouilova, L. S., Ullrich, F. A., Patil, K. D., Romberger, D. J., Floreani, A. A. and Anderson, J. R. (2002) Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device that primarily heats tobacco. Nicotine & Tobacco Research, 4:4, pp. 467-476.
85. Rodu, B. and Cole, P. (1999) Nicotine maintenance for inveterate smokers. Technology, 6, pp. 17-21.
86. Roethig, H. J., Kinser, R. D., Lau, R. W., Walk, R. A. and Wang, N. (2005) Long-term exposure evaluation of adult smokers switching from conventional to first-generation electrically heated cigarettes during controlled smoking. Journal of Clinical Pharmacology, 45:2, pp. 133-145.
87. Roethig, H. J., Zedler, B. K., Kinser, R. D., Feng, S., Nelson, B. L. and Liang, Q. (2007) Short-term clinical exposure evaluation of a second-generation electrically heated cigarette smoking system. Journal of Clinical Pharmacology, 47:4, pp. 518-530.
88. Rosengren, A., Wilhelmsen, L. and Wedel, H. (1992) Coronary heart disease, cancer and mortality in male middle-aged light smokers. Journal of Internal Medicine, 231:4, pp. 357-362.
89. Scherer, G., Engl, J., Urban, M., Gilch, G., Janket, D. and Riedel, K. (2007) Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regulatory Toxicology and Pharmacology, 47:2, pp. 171-183.
90. Schildt, E., Eriksson, M., Hardell, L. and Magnusson, A. (1998) Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. International Journal of Cancer, 77, pp. 341-346.
91. Shiffman, S., Mason, K. M. and Henningfield, J. E. (1998) Tobacco dependence treatments: Review and prospectus. Annual Review of Public Health, 19, pp. 335-358.
92. Shiffman, S., Pillitteri, J. L., Burton, S. L., Rohay, J. M. and Gitchell, J. G. (2001) Smokers' beliefs about "light" and "ultra" light cigarettes. Tobacco Control, 10, pp. i17-i23.
93. Smith, C. J., McKarns, S. C., Davis, R. A., Livingston, S. D., Bombick, B. R., Avalos, J. T., Morgan, W. T. and Doolittle, D. J. (1996) Human urine mutagenicity study comparing cigarettes which burn or primarily heat tobacco. Mutation Research, 361:1, pp. 1-9.
94. Stepanov, I., Jensen, J., Hatsukami, D. and Hecht, S. S. (2006) Tobacco-specific nitrosamines in new tobacco products. Nicotine & Tobacco Research, 8:2, pp. 309-313.
95. Stewart, J. C., Hyde, R. W., Boscia, J., Chow, M. Y., O'Mara, R. E., Perillo, I., Pietropaoli, A., Smith, C. J., Torres, A., Utell, M. J. and Frampton, M. W. (2006) Changes in markers of epithelial permeability and inflammation in chronic smokers switching to a nonburning tobacco device (Eclipse). Nicotine & Tobacco Research, 8:6, pp. 773-783.
96. (2001) Clearing the smoke: Assessing the science base for tobacco harm reduction, National Academies Press, Washington, DC
97. Thun, M., Day-Lally, C., Calle, E., Flanders, W. and Heath, C. (1995) Excess mortality among cigarette smokers: Changes in a 20-year interval. American Journal of Public Health, 85:9, pp. 1223-1230.
98. Tomar, S. L. (2006) Epidemiological perspective for tobacco risk reduction
99. Tomar, S. L., Giovino, G. A. and Eriksen, M. P. (1995) Smokeless tobacco brand preference and brand switching among US adolescents and young adults. Tobacco Control, 4, pp. 67-72.
100. Tonnesen, P., Pisinger, C., Hvidberg, S., Wennike, P., Bremann, L., Westin, A., Thomsen, C. and Nilsson, F. (2005) Effects of smoking cessation and reduction in asthmatics. Nicotine & Tobacco Research, 7:1, pp. 139-148.
101. Tverdal, A. and Bjartveit, K. (2006) Health consequences of reduced daily cigarette consumption. Tobacco Control, 15:6, pp. 472-480.
102. Tyndale, R. F. and Sellers, E. M. (2002) Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Therapeutic Drug Monitoring, 24:1, pp. 163-171.
103. U.S. Department of Health & Human Services (2000) Reducing tobacco use: A report of the surgeon general, Author, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA
104. U.K. Department of Health (1998) Smoking kills. A white paper on tobacco, The Stationery Office, London
105. UN Focal Point on Tobacco or Health (1998) Social and economic aspects of reduction of tobacco smoking by use of alternative nicotine delivery systems (ANDS), United Nations, Geneva
106. von Weymarn, L. B., Brown, K. M. and Murphy, S. E. (2006) Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. The Journal of Pharmacology and Experimental Therapeutics, 316:1, pp. 295-303.
107. Warner, K. E. and Burns, D. M. (2003) Hardening and the hard-core smoker: Concepts, evidence, and implications. Nicotine & Tobacco Research, 5, pp. 37-48.
108. Wewers, M. E., Stillman, F. A., Hartman, A. M. and Shopland, D. R. (2003) Distribution of daily smokers by stage of change: Current Population Survey results. Preventive Medicine, 36:6, pp. 710-720.
109. Wynder, E. and Stellman, S. (1979) Impact of long-term filter cigarette usage on lung and larynx cancer risk: A case-control study. Journal of the National Cancer Institute, 62, pp. 471-477.
110. Zedler, B. K., Kinser, R., Oey, J., Nelson, B., Roethig, H. J., Walk, R. A., Kuhl, P., Rustemeier, K., Schepers, G., Von Holt, K. and Tricker, A. R. (2006) Biomarkers of exposure and potential harm in adult smokers of 3-7 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers. Biomarkers, 11:3, pp. 201-220.